DE69123960D1 - Behandlung von entzündungen - Google Patents

Behandlung von entzündungen

Info

Publication number
DE69123960D1
DE69123960D1 DE69123960T DE69123960T DE69123960D1 DE 69123960 D1 DE69123960 D1 DE 69123960D1 DE 69123960 T DE69123960 T DE 69123960T DE 69123960 T DE69123960 T DE 69123960T DE 69123960 D1 DE69123960 D1 DE 69123960D1
Authority
DE
Germany
Prior art keywords
treatment
inflammation
cells
mast
mediators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69123960T
Other languages
English (en)
Other versions
DE69123960T2 (de
Inventor
John Lezdey
Allan Wachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sonoran Desert Chemicals Scottsdale Ariz LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27416749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69123960(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/683,620 external-priority patent/US5190917A/en
Application filed by Individual filed Critical Individual
Publication of DE69123960D1 publication Critical patent/DE69123960D1/de
Application granted granted Critical
Publication of DE69123960T2 publication Critical patent/DE69123960T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69123960T 1990-10-16 1991-09-26 Behandlung von entzündungen Expired - Fee Related DE69123960T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59824190A 1990-10-16 1990-10-16
US64372791A 1991-01-18 1991-01-18
US07/683,620 US5190917A (en) 1986-12-24 1991-04-11 Treatment of psoriasis
PCT/US1991/006847 WO1992006706A1 (en) 1990-10-16 1991-09-26 Treatment of inflammation

Publications (2)

Publication Number Publication Date
DE69123960D1 true DE69123960D1 (de) 1997-02-13
DE69123960T2 DE69123960T2 (de) 1997-05-07

Family

ID=27416749

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69123960T Expired - Fee Related DE69123960T2 (de) 1990-10-16 1991-09-26 Behandlung von entzündungen

Country Status (10)

Country Link
EP (1) EP0512090B2 (de)
AT (1) ATE146970T1 (de)
AU (1) AU679165B2 (de)
CA (1) CA2091354C (de)
DE (1) DE69123960T2 (de)
DK (1) DK0512090T4 (de)
ES (1) ES2096665T3 (de)
GR (1) GR3022533T3 (de)
OA (1) OA09768A (de)
WO (1) WO1992006706A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4244735A1 (de) * 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US5614198A (en) * 1995-07-25 1997-03-25 The Trustees Of The University Of Pennsylvania Bowman-Birk Inhibitor compositions for treatment of inflammatory disease
DE19600480A1 (de) * 1996-01-09 1997-07-10 Beiersdorf Ag Verwendung von Serin-Proteinasen gegen Akne und entzündete Comedonen
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
EP0834556A1 (de) * 1996-09-25 1998-04-08 Academisch Ziekenhuis Leiden Verfahren zur Zellkultivierung
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
JP2002526382A (ja) * 1998-04-01 2002-08-20 バイオテック・オーストラリア・ピーティーワイ・リミテッド 皮膚創傷の治療へのプロテアーゼ阻害剤の使用
EP1163900A1 (de) * 1998-11-05 2001-12-19 Protease Sciences, Incorporated Kosmetische Zubereitung human-typische Serin-Protease-Inhibitoren enthaltend
EP1150699A4 (de) * 1999-02-01 2004-06-30 John Lezdey Behandlung der blasen- und gastrointestinalen-mastozytose
JP2002537346A (ja) * 1999-02-22 2002-11-05 エリック・エフ・バーンスタイン 光老化の保護用組成物および保護方法
WO2001030389A1 (fr) 1999-10-26 2001-05-03 Japan Tissue Engineering Co., Ltd. Inhibiteurs de contraction de blessure
ES2243314T3 (es) 1999-10-27 2005-12-01 Alexandra Lucas Composiciones para la prevencion y el tratamiento del rechazo de trasplantes.
WO2001064031A2 (en) * 2000-03-01 2001-09-07 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Slpi knockout mice and methods for wound treatment
EP1365798B1 (de) 2000-09-29 2009-12-30 Viron Therapeutics, Inc. Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DK1392354T3 (da) * 2001-04-30 2005-07-04 Switch Biotech Ag Anvendelse af alpha-1-antichymotrypsin til fremstillingen af en sammensætning til behandling, forebyggelse eller diagnose af dårligt helende diabetiske sår
EP1390062A4 (de) * 2001-05-02 2005-09-14 Blood Res Center Modulatoren der elastase-inhibitor-sekretion
GB0125594D0 (en) * 2001-10-25 2001-12-19 Univ Sheffield Inhibitors for inactivating allergens
EP1415664A1 (de) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Verwendung von Alpha-1-antichymotrypsin in Kombination mit Alpha-1-antitrypsin zur Behandlung/Vorbeugung von schlecht heilenden arteriellen oder diabetischen Wunden
DE60328909D1 (de) * 2002-11-20 2009-10-01 Arriva Prometic Inc Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
WO2005056044A1 (en) * 2003-10-23 2005-06-23 Terry Du Clos Use of c-reactive protein to treat immune complex-mediated renal disease
GB0411145D0 (en) * 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2008060362A2 (en) * 2006-09-27 2008-05-22 The Regents Of The University Of California Methods and compositions for the treatment of skin diseases and disorders
EP2611459B1 (de) 2010-08-31 2019-12-11 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Alpha-1 Antitrypsin abgeleitete Polypeptide zur Verwendung in der Behandlung von Entzündung
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
AU2012272636A1 (en) 2011-06-24 2013-05-02 Advent Bio Holdings Llc Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
BR112014027333A2 (pt) * 2012-05-01 2017-07-18 Univ Duke composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados
AR094778A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteínas con glicosilación modificada y métodos para producirlas
US9801848B2 (en) * 2013-03-13 2017-10-31 The Regents Of The University Of California Prevention of rosacea inflammation
EP3487875A4 (de) * 2016-07-19 2020-02-12 Arete Discoveries, Inc. Biomarker für den nachweis und die behandlung von mastzellenaktivitätsbedingten erkrankungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304971B1 (de) 1982-08-13 1998-02-04 ZymoGenetics, Inc. Verfahren zur Herstellung eines Polypeptids mit der Proteasehemmenden Aktivität von Säugetier-alpha-1-Antitrypsin
AU3145184A (en) * 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US5093316A (en) 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化

Also Published As

Publication number Publication date
AU679165B2 (en) 1997-06-26
EP0512090B1 (de) 1997-01-02
EP0512090B2 (de) 2006-11-22
ATE146970T1 (de) 1997-01-15
CA2091354C (en) 2005-04-12
EP0512090A1 (de) 1992-11-11
DK0512090T3 (da) 1997-06-16
AU8929091A (en) 1992-05-20
GR3022533T3 (en) 1997-05-31
CA2091354A1 (en) 1992-04-17
DK0512090T4 (da) 2007-01-15
ES2096665T3 (es) 1997-03-16
OA09768A (en) 1993-11-30
DE69123960T2 (de) 1997-05-07
EP0512090A4 (en) 1993-05-05
WO1992006706A1 (en) 1992-04-30

Similar Documents

Publication Publication Date Title
ATE146970T1 (de) Behandlung von entzündungen
EA200101166A1 (ru) Ингибиторы металлопротеаз
DK0380367T3 (da) Præparater og fremgangsmåde til sygdomsbehandling
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
IT1138543B (it) L'applicazione in terapeutica dei derivati del 4,5,6,7-tetraidroisossazolo(5,4-c)piridin-3-olo come miotonolitici
PT92821A (pt) Processo para a preparacao composicoes farmaceuticas para o combate de doencas do tipo psoriase, bem como doencas inflamatorias, incorporando azelastina como substancia activa
ATE107515T1 (de) Zusammensetzung zur behandlung von entzündung.
ATE80302T1 (de) Verwendung von polymeren bei einer behandlung.
ES2058125T3 (es) Derivados de piperidina para el tratamiento del dolor.
DK0658110T3 (da) Anvendelse af norastemizol til behandling af allergisk rhinitis
ES2114117T3 (es) Acidos fenilalcan(en)oicos con actividad antagonista del leucotrieno b4.
DE68903092D1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
DE69125855D1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
ES2032922T3 (es) Empleo de los paf-aceter antagonicos para la fabricacion de un medicamento y procedimiento para determinar la eficacia de los mismos.
DE69108748D1 (de) Antithrombin-Lösung und ihre Verwendung.
ES2166838T3 (es) 6-(triazolil(3-(trifluorometil)fenil)metil)-2-quinolinonas y -quinolinationas.
ES252138Y (es) Zapato ortopedico perfeccionado con punta automaticamente elevable al levantar el pie
SE8902607D0 (sv) Oxaza heterocycles and pharmaceutical compositions containing same
ES2036533T3 (es) Derivados de 1,6-naftiridina, procedimientos para su obtencion y de medicamentos que los contienen para el tratamiento de enfermedades de los vasos sanguineos.
ITMI920979A1 (it) N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico.
ATE120447T1 (de) Polyamin-derivate als antineoplastische mittel.
ES517341A0 (es) Prensa hidraulica embaladora automatica y autodesinfectable para la eliminacion y el tratamiento en condiciones higienicas adecuadas de los residuos clinicos y hospitalarios infectados.
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
DK0673646T3 (da) Anvendelse af deoxyspergualin til fremstilling af et lægemiddel til behandling af inflammatorisk-hyperreaktive sygdomme

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: SONORAN DESERT CHEMICALS LLC, SCOTTSDALE, ARIZ.,

8381 Inventor (new situation)

Inventor name: LEZDEY, JOHN, CHERRY HILL, N.J., US

Inventor name: WACHTER, ALLAN, TEMPE, ARIZ., US

8328 Change in the person/name/address of the agent

Representative=s name: HENKEL, FEILER & HAENZEL, 80333 MUENCHEN

8366 Restricted maintained after opposition proceedings
8339 Ceased/non-payment of the annual fee